These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 30463981)

  • 1. Increased Frequency of Virus Shedding by Herpes Simplex Virus 2-Infected Guinea Pigs in the Absence of CD4
    Bourne N; Perry CL; Banasik BN; Miller AL; White M; Pyles RB; Schäfer H; Milligan GN
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30463981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4
    Srivastava R; Roy S; Coulon PG; Vahed H; Prakash S; Dhanushkodi N; Kim GJ; Fouladi MA; Campo J; Teng AA; Liang X; Schaefer H; BenMohamed L
    J Virol; 2019 May; 93(9):. PubMed ID: 30787156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic prime/pull vaccination of HSV-2-infected guinea pigs with the ribonucleotide reductase 2 (RR2) protein and CXCL11 chemokine boosts antiviral local tissue-resident and effector memory CD4
    Quadiri A; Prakash S; Dhanushkodi NR; Singer M; Zayou L; Shaik AM; Sun M; Suzer B; Lau LSL; Chilukurri A; Vahed H; Schaefer H; BenMohamed L
    J Virol; 2024 May; 98(5):e0159623. PubMed ID: 38587378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus-specific immune memory at peripheral sites of herpes simplex virus type 2 (HSV-2) infection in guinea pigs.
    Xia J; Veselenak RL; Gorder SR; Bourne N; Milligan GN
    PLoS One; 2014; 9(12):e114652. PubMed ID: 25485971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
    J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells.
    Khan AA; Srivastava R; Chentoufi AA; Geertsema R; Thai NT; Dasgupta G; Osorio N; Kalantari M; Nesburn AB; Wechsler SL; BenMohamed L
    J Virol; 2015 Jul; 89(13):6619-32. PubMed ID: 25878105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boosting of vaginal HSV-2-specific B and T cell responses by intravaginal therapeutic immunization results in diminished recurrent HSV-2 disease.
    Bourne N; Keith CA; Miller AL; Pyles RB; Cohen G; Milligan GN
    J Virol; 2023 Sep; 97(9):e0066923. PubMed ID: 37655939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
    Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
    PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of herpes simplex virus type 2 (HSV-2) -specific cell-mediated immune responses in guinea pigs during latent HSV-2 genital infection.
    Perry CL; Banasik BN; Gorder SR; Xia J; Auclair S; Bourne N; Milligan GN
    J Immunol Methods; 2016 Dec; 439():1-7. PubMed ID: 27659010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection.
    Johnston C; Zhu J; Jing L; Laing KJ; McClurkan CM; Klock A; Diem K; Jin L; Stanaway J; Tronstein E; Kwok WW; Huang ML; Selke S; Fong Y; Magaret A; Koelle DM; Wald A; Corey L
    J Virol; 2014 May; 88(9):4921-31. PubMed ID: 24554666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.
    Awasthi S; Lubinski JM; Shaw CE; Barrett SM; Cai M; Wang F; Betts M; Kingsley S; Distefano DJ; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM
    J Virol; 2011 Oct; 85(20):10472-86. PubMed ID: 21813597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Role for Interleukin-17 in Enhancing Type 1 Helper T Cell Immunity in the Female Genital Tract following Mucosal Herpes Simplex Virus 2 Vaccination.
    Bagri P; Anipindi VC; Nguyen PV; Vitali D; Stämpfli MR; Kaushic C
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital Mucosa.
    Schiffer JT; Swan DA; Magaret A; Schacker TW; Wald A; Corey L
    PLoS One; 2016; 11(6):e0155124. PubMed ID: 27285483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes.
    Bernstein DI; Pullum DA; Cardin RD; Bravo FJ; Dixon DA; Kousoulas KG
    Vaccine; 2019 Jan; 37(1):61-68. PubMed ID: 30471955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A nonhuman primate model for genital herpes simplex virus 2 infection that results in vaginal vesicular lesions, virus shedding, and seroconversion.
    Wang K; Jordan T; Dowdell K; Herbert R; Moore IN; Koelle DM; Cohen JI
    PLoS Pathog; 2024 Sep; 20(9):e1012477. PubMed ID: 39226323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.
    Bourne N; Milligan GN; Stanberry LR; Stegall R; Pyles RB
    J Infect Dis; 2005 Dec; 192(12):2117-23. PubMed ID: 16288376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCL10/CXCR3-Dependent Mobilization of Herpes Simplex Virus-Specific CD8
    Srivastava R; Khan AA; Chilukuri S; Syed SA; Tran TT; Furness J; Bahraoui E; BenMohamed L
    J Virol; 2017 Jul; 91(14):. PubMed ID: 28468883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of disease and immunity at the genital epithelium following intrarectal inoculation of male guinea pigs with herpes simplex virus type 2.
    Bourne N; Banasik BN; Perry CL; Miller AL; White M; Pyles RB; Milligan GN
    Virology; 2019 Jan; 526():180-188. PubMed ID: 30412859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs.
    Skoberne M; Cardin R; Lee A; Kazimirova A; Zielinski V; Garvie D; Lundberg A; Larson S; Bravo FJ; Bernstein DI; Flechtner JB; Long D
    J Virol; 2013 Apr; 87(7):3930-42. PubMed ID: 23365421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.